2026 Southern Hemisphere Influenza Vaccine
Closed Pre-Solicitation Posted
Not the latest version. See the latest solicitation from .
- Solicitation number
- SPE2DP25R0004
- Agency
-
Medical Supply Chain
Troop Support, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Defense Logistics Agency- Troop Support is seeking sources capable of providing Southern Hemisphere Influenza Vaccine for the 2026 season through this pre-solicitation notice. The vaccine must be trivalent, FDA-licensed, and intended for active immunization against influenza in the Southern Hemisphere, meeting minimum FDA formula requirements as determined by the Vaccines and Related Biological Products Advisory Committee. Each dose must be pre-measured at 0.5ML in pre-filled syringes for intramuscular administration, free of thimerosal or other preservatives, and suitable for healthy individuals aged 6 months and older. The vaccine must be shipped refrigerated between 2-8°C without freezing and packaged in units containing 10 pre-filled syringes. This request for information does not commit the government to issue a solicitation or make an award, and responses are due by August 4, 2025, to be submitted electronically to the designated contracting specialist.
This procurement does not include any set-aside designations and no current contractors or incumbents are identified in the notice. DLA Troop Support has an estimated annual requirement of 60,000 doses for the 2026 season, though quantities may fluctuate based on service requirements. The desired delivery timeframe is mid-March 2026 to the Defense Distribution Center in Susquehanna, PA. The agency is requesting detailed information from potential suppliers about their current manufacturing capabilities, FDA registration status, pricing, inventory levels, delivery timelines, and surge capacity requirements. Companies with products under development are also invited to provide information about their current development stage and any testing completed, as the data will inform DLA's procurement strategy development.
Notice text
2 versions
Update #2 · Latest ·
The Defense Logistics Agency- Troop Support is seeking sources capable of providing Southern Hemisphere Influenza Vaccine for 2026 season. Shall be trivalent vaccine, licensed by the FDA, intended for active immunization for the prevention of influenzas for the Southern Hemisphere. Shall meet the minimum formula for the influenza vaccine as determined by the FDA’s Vaccines and Related Biological Products Advisory Committee. Shall be pre-measured 0.5ML dose, each dose shall be pre-filled in a commercially available syringe for intramuscular administration in healthy individuals aged 6 months and older. Shall be free of thimerosal or other preservatives. Shall be shipped refrigerated between 2° and 8° C. The vaccine must not be frozen. Shall be one package containing 10 pre-filled syringes as the unit of issue. Product shall be both FDA Approved and ACIP Recommended.
DLA Troop Support has an annual estimated requirement for Southern Hemisphere Influenza Vaccine of 60,000 doses for the 2026 season. However, the quantity may increase or decrease as the Services requirements change. The vaccine shall be delivered to the Defense Distribution Center (DDC) in Susquehanna, PA, and the desirable delivery time is mid-March 2026.
This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not be returned.
*** Currently Marketed Southern Hemisphere Influenza***
If your firm currently markets Southern Hemisphere Influenza Vaccine, please provide information with respects to the following:
- Place of Manufacture
- Estimated Annual Capacity
- FDA Registration information
- Product Name and description including description of any special features
- Current unit sales price
- Estimated inventory level and storage requirements
- Delivery days for this item and earliest product available time
- Capacity for surge and sustainment requirement
- Country of origin for API
- Do you have any authorized distributor for this item in the U.S.? If so, please provide the name of the authorized distributor(s).
***New Product Under Development***
For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture product described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.
Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Southern Hemisphere Influenza Vaccine for 2026 season. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.
Your response to this RFI may be submitted electronically in PDF format and emailed to Contracting Specialist Rosbert.Jones@dla.mil.
Update #1 ·
The Defense Logistics Agency- Troop Support is seeking sources capable of providing Southern Hemisphere Influenza Vaccine for 2026 season. Shall be trivalent vaccine, licensed by the FDA, intended for active immunization for the prevention of influenzas for the Southern Hemisphere. Shall meet the minimum formula for the influenza vaccine as determined by the FDA’s Vaccines and Related Biological Products Advisory Committee. Shall be pre-measured 0.5ML dose, each dose shall be pre-filled in a commercially available syringe for intramuscular administration in healthy individuals aged 6 months and older. Shall be free of thimerosal or other preservatives. Shall be shipped refrigerated between 2° and 8° C. The vaccine must not be frozen. Shall be one package containing 10 pre-filled syringes as the unit of issue. Product shall be both FDA Approved and ACIP Recommendation.
DLA Troop Support has an annual estimated requirement for Southern Hemisphere Influenza Vaccine of 60,000 doses for the 2026 season. However, the quantity may increase or decrease as the Services requirements change. The vaccine shall be delivered to the Defense Distribution Center (DDC) in Susquehanna, PA, and the desirable delivery time is mid-March 2026.
This is a request for information (RFI) and does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to the RFI. All submitted information shall remain with the U.S. Government and will not be returned.
*** Currently Marketed Southern Hemisphere Influenza***
If your firm currently markets Southern Hemisphere Influenza Vaccine, please provide information with respects to the following:
- Place of Manufacture
- Estimated Annual Capacity
- FDA Registration information
- Product Name and description including description of any special features
- Current unit sales price
- Estimated inventory level and storage requirements
- Delivery days for this item and earliest product available time
- Capacity for surge and sustainment requirement
- Country of origin for API
- Do you have any authorized distributor for this item in the U.S.? If so, please provide the name of the authorized distributor(s).
***New Product Under Development***
For products under development, describe the current stage of development and whether the product has undergone independent laboratory testing or FDA testing/trials etc. Firms and organizations that currently develop or manufacture product described in this RFI or that have technologies, pharmaceuticals, or manufacturing capabilities under development are invited to submit information to DLA Troop Support.
Data obtained from this Request For Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Southern Hemisphere Influenza Vaccine for 2025 season. All information submitted will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Information Act of 2002.
Your response to this RFI may be submitted electronically in PDF format and emailed to Contracting Specialist Rosbert.Jones@dla.mil.
Notice history
| Notice | Type | Posted |
|---|---|---|
| 2026 Southern Hemisphere Influenza Vaccine | Limited / Sole Source Justification | |
| 2026 Southern Hemisphere Influenza Vaccine | Solicitation | |
| 2026 Southern Hemisphere Influenza Vaccine | Pre-Solicitation | |
| This notice | Pre-Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| Request for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response | Office of the Assistant Secretary for Preparedness and Response | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity